Procter & Gamble (PG) · Stock analysis
Are Analysts Right About PG Stock?
By Quotelinks ·

Wall Street analysts hold a cautious stance on The Procter & Gamble Company as shares trade near record levels. The stock ended trading on November 19, 2026, at $167.85, just shy of its 52-week peak. Across 25 covering analysts, the consensus average rating sits at 3.84 on a scale where 5 represents strong buy and 1 indicates strong sell. Meanwhile, the consensus mean price target of $173.65 indicates potential upside of 3.5%, trailing the median S&P 500 Consumer Defensive sector upside target of 4.7%.
Earnings expectations have experienced slight downward revisions across upcoming fiscal horizons. For the fiscal year ending June 30, 2026, consensus expectations fell 0.9% over 90 days to $6.88 per share. The broader business continues to demonstrate operational stability, supported by trailing twelve month net income of $16.03 billion on revenue of $87.92 billion. While the company has surpassed earnings projections in each of the past eight quarters, the narrow premium between current prices and average target levels suggests analysts see limited room for rapid price appreciation.
What Do Analysts Rate PG, and Where Is the Price Target?
Covering analysts assign The Procter & Gamble Company an average rating of 3.84, pointing to an overall tilt toward neutral sentiment. Of the 25 analysts issuing ratings on the stock, 12 maintain Hold recommendations, making it the single largest category. Eight analysts label the shares a Strong Buy, while five recommend a Buy. Notably, zero analysts maintain Sell or Strong Sell ratings on the company, indicating that professional sentiment remains free of outright negative designations.
The consensus mean price target across these analysts is $173.65, which sits 3.5% above the closing quote of $167.85. This gap leaves little room beneath the 52-week high of $173.02, reflecting an expectation that shares will remain close to their upper trading boundary. By comparison, the median S&P 500 Consumer Defensive peer carries an expected upside of 4.7%, showing that analysts anticipate less forward price expansion from this household product manufacturer than from peer consumer stocks.
Valuation metrics provide context for these targets. The business commands a trailing price-to-earnings multiple of 25.8x and a forward price-to-earnings multiple of 24.5x. Total market capitalization is $397.00 billion, with the shares trading at a price-to-sales ratio of 4.5x. These multiples reflect an established valuation premium, while the underlying free cash flow yield sits at 3.9%. Investors also receive a dividend yield of 2.56%, supported by an enterprise balance sheet with debt to equity of 0.71.
For bulls, the absence of any Sell ratings confirms the defensive strengths of a consumer giant with 104,000 employees and a 21.4% return on invested capital. For bears, a price target offering only 3.5% upside suggests the stock is already pricing in its predictable operational performance. With the stock trading far above its 52-week low of $138.04, Wall Street's price targets reflect steady expectations rather than anticipation of rapid capital gains.
Which Way Have PG Earnings Estimates Moved?
Earnings per share estimates for The Procter & Gamble Company have drifted moderately downward across every measured forward period over the past 90 days. For the fiscal year ending June 30, 2026, the consensus EPS estimate stands at $6.88 among 24 analysts, down 0.9% from $6.94 three months ago. Over the trailing 30 days for that same full-year target, zero analysts raised their numbers while two analysts reduced their projections, signaling persistent downward adjustments.
Shorter-term quarterly revisions reveal similar downward adjustments over the 90-day window. For the quarter ending September 30, 2026, 19 analysts project an EPS of $1.89, representing a 1.5% decrease from $1.92 ninety days earlier. In the last 30 days, four analysts raised estimates while one cut. For the quarter ending December 31, 2026, the projection dropped 3.4% from $1.88 to $1.81 across 20 analysts. Recent activity shows three positive revisions against two negative revisions.
Looking into calendar year 2027, the quarter ending March 31, 2027, carries an estimate of $1.63 among 16 analysts, falling 1.6% from $1.66 ninety days prior. Over the past 30 days, three analysts raised projections while four lowered them. For the full fiscal year ending June 30, 2027, the consensus estimate is $6.98, lower by 0.5% compared to $7.01 ninety days earlier. In that period, three analysts adjusted upward and three cut their estimates over the last month.
Longer-range projections show minimal movement. For the fiscal year ending June 30, 2028, 20 analysts project EPS of $7.40, a minor 0.1% decline from $7.41 three months ago, with two positive and three negative revisions in the last 30 days. Across the board, every single measured time frame has experienced a small reduction in consensus earnings expectations over the 90-day review period, curbing expectations for near-term profit growth.
How Has PG Done Against Estimates and the Market?
The company has demonstrated steady execution by topping earnings expectations in 8 of 8 recent quarters. Despite consistent minor cuts to consensus expectations prior to reporting, Procter & Gamble has beaten consensus EPS forecasts in every reporting period over the past two years. This reliability underpins the stock's low-volatility profile, with beta registered at 0.34, showing substantially smaller swings than the broader equities market.
Top-line growth has stayed stable, with the latest quarter delivering year-over-year revenue growth of 4.0%. Over a longer horizon, the company has generated three-year annualized revenue growth of 2.0% per year. Operational margins remain high, including a gross margin of 49.8%, an operating margin of 26.9%, and a net margin of 18.2%. These figures show that while sales expansion is measured, the business retains considerable pricing power and converts top-line revenue efficiently into bottom-line profits.
Over shorter horizons, share returns have exceeded benchmark indexes. Year to date, the stock has gained 20.5%, outperforming the S&P 500, as tracked by SPY, which returned 5.8%. Looking back over one full year, shares advanced 17.5%, while the S&P 500 rose 9.2%. The stock's defensive attributes and operational stability helped propel the share price upward across both periods, outpacing broader market benchmarks.
The longer three-year picture presents an opposing contrast. Over three years, the company delivered a total return of 20.3%. In that same span, the S&P 500 generated a total return of 64.7%. While the company has maintained steady results and consistent quarterly beats, its three-year return trailed the broader market substantially during wider market rallies, highlighting the trade-off of a defensive portfolio allocation.
Investors should watch how the company tracks against its revised full-year EPS projection of $6.88 for the period ending June 30, 2026. Maintaining its perfect record of 8 of 8 EPS beats will be critical to supporting current multiples, including its forward price-to-earnings ratio of 24.5x. Shareholders will also monitor whether quarterly revenue growth can sustain its 4.0% pace while holding operating margins near 26.9%. If earnings revisions begin turning upward from the current $6.88 baseline, Wall Street could raise its $173.65 mean price target closer to, or beyond, the current 52-week peak.
Figures as of November 19, 2026. For information only, not investment advice.